摘要
目的评价石杉碱甲治疗阿尔茨海默病(Alzheimer's disease,AD)的临床疗效和安全性。方法将60例轻、中度AD患者随机分为石杉碱甲组(治疗组)和安慰剂组(对照组),各30例。治疗组给予石杉碱甲片0.2 mg,2次/d口服;对照组口服安慰剂,2次/d口服。疗程均为12周。治疗前后分别测定记忆商(Memory Quo-tient,MQ)、简易智力状态检查(Mini-mental state examination,MMSE)、长谷川痴呆修正量表(HDS-R)、工具性日常生活活动能力量表(ADL)的变化。结果治疗12周后,治疗组AD患者MQ、MMSE积分显著提高(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.01);ADL积分降低,与治疗前比较,差异有统计学意义(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.01)。结论石杉碱甲片对轻、中度AD有较好疗效,且副作用较少,是安全性较好的药物。
Objective To evaluate the clinical effect and safety of huperzine A on the patients with mild and moderate Alzheimer disease （AD）. Methods 60 patients with mild and moderate AD were randomly divided into treatment group （ n = 30 ） and control group （ n = 30） , treatment group was treated with huperzine A （ 0. 2 mg, twice dai-ly） and control group was treated with placebo for 12 weeks. Memory Quotient（MQ） , Mini-mental state examination （MMSE） ,HDS-R and ADL were measured respectively before treatment and after 12 weeks treatment. Results After 12 weeks treatment, MQ and MMSE in treatment group were obviously higher （ P 〈 0. 01 ）, and they were obviously higher than that in control group （ P 〈 0. 01 ） ; ADL was obviously lower （ P 〈 0. 01 ）, and it was also lower than that of control group（ P 〈 0. 01 ）. Conclusion Huperzine A is safe and effective in the treatment for the patients with mild and moderate AD.
出处
《实用药物与临床》
CAS
2013年第1期37-38,共2页
Practical Pharmacy and Clinical Remedies
